心房颤动相关心肌纤维化生物学标志物研究进展  

Advances in the Biomarkers of Myocardial Fibrosis Related to Atrial Fibrillation

作　　者：陈阳 凌智瑜[1] 

机构地区：[1]重庆医科大学附属第二医院心血管内科,重庆

出　　处：《临床医学进展》2023年第3期3815-3821,共7页Advances in Clinical Medicine

摘　　要：心房颤动是临床上最常见类型心律失常,随着老龄化社会到来,其发病率日益增加,社会、经济负担随之加重。心房颤动导管消融治疗虽已取得巨大成功,但术后复发率仍较高。目前认为心肌纤维化尤其是心房肌纤维化与心房颤动的发生及消融术后房颤的复发密切相关。心肌纤维化生物学标志物检测作为一种更为便捷、经济的评估心肌纤维化方法,有望在心房颤动治疗方式选择、预后评估中发挥重要作用。Atrial fibrillation is the most common type of arrhythmia in clinical practice. With the coming of the aging society, its incidence is increasing, and the social and economic burden is increasing. Although catheter ablation of atrial fibrillation has achieved great success, the postoperative recurrence rate is still high. Currently, it is believed that myocardial fibrosis, especially atrial fibrosis, is closely re-lated to the occurrence of atrial fibrillation and the recurrence of atrial fibrillation after ablation. As a more convenient and economical method to evaluate myocardial fibrosis, biomarker detection of myocardial fibrosis is expected to play an important role in the treatment choice and prognosis evaluation of atrial fibrillation.

关 键 词：心房颤动 心肌纤维化 生物学标志物 

分 类 号：R54[医药卫生—心血管疾病]